FcgRIIIA (CD16)-expressing Monocytes Mediate the Depletion of Tumor-Infiltrating Tregs via Ipilimumab-Dependent ADCC in Melanoma Patients

Journal for ImmunoTherapy of Cancer - United Kingdom
doi 10.1186/2051-1426-2-s3-o14
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

CD8+ Enriched "Young" Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma

Clinical Cancer Research
Cancer ResearchOncology
2010English

Tumor-Infiltrating Lymphocytes in Melanoma

Current Oncology Reports
Oncology
2012English

Bevacizumab Plus Ipilimumab in Patients With Metastatic Melanoma

Cancer immunology research
Cancer ResearchImmunology
2014English

Immunologic Heterogeneity of Tumor-Infiltrating Lymphocyte Composition in Primary Melanoma

Human Pathology
Forensic MedicinePathology
2016English

Linking Tumor Growth Dynamics to Survival in Ipilimumab‐Treated Patients With Advanced Melanoma Using Mixture Tumor Growth Dynamic Modeling

CPT: Pharmacometrics and Systems Pharmacology
ModelingSimulationCardiovascular MedicinePharmacologyCardiology
2019English

Ipilimumab for the Treatment of Advanced Melanoma in Six Kidney Transplant Patients

American Journal of Transplantation
TransplantationAllergyImmunologyPharmacology
2018English

Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma

Clinical Cancer Research
Cancer ResearchOncology
2019English

Clinical Immunology Gastric Cancer Increase the Percentage of Intermediate (CD14++CD16+) and Nonclassical (CD14+CD16+) Monocytes

Central-European Journal of Immunology
AllergyImmunology
2012English

Adjuvant Ipilimumab in High-Risk Uveal Melanoma

Cancers
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy